Use of cannabinoids in the treatment of epilepsy
US-2016166515-A1 · Jun 16, 2016 · US
Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
US9522123B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9522123-B2 |
| Application number | US-201414579061-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 22, 2014 |
| Priority date | Jul 3, 2009 |
| Publication date | Dec 20, 2016 |
| Grant date | Dec 20, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating complex partial seizure comprising administering cannabidiol (CBD) to a patient wherein the CBD is present in an amount which provides a daily dose of at least 400 mg. 2. The method of claim 1 , wherein CBD is present in an amount which provides a daily dose of from 400 to 800 mg. 3. The method of claim 1 , wherein the CBD is used in combination with tetrahydrocannabivarin (THCV). 4. The method of claim 3 , wherein the THCV is present in an amount which provides a daily dose of at least 1.5 mg. 5. The method of claim 4 , wherein the THCV is present in an amount which provides a daily dose of at least 15 mg. 6. The method of claim 1 , wherein the CBD is present as a plant extract. 7. The method of claim 6 , wherein the plant extract comprises less than 5% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract. 8. The method of claim 7 , wherein the plant extract comprises less than 1% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract. 9. The method of claim 1 , wherein the CBD is present as a pure or isolated cannabinoid. 10. The method of claim 3 , wherein the CBD in combination with THCV is present as a plant extract. 11. The method of claim 10 , wherein the plant extract comprises less than 5% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract. 12. The method of claim 11 , wherein the plant extract comprises less than 1% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract. 13. The method of claim 3 , wherein the CBD in combination with THCV is present as a pure or isolated cannabinoid.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9522123B2 cover?
- This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has …
- Who is the assignee on this patent?
- Gw Pharma Ltd, Otsuka Pharma Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/658. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).